Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKesson
Boehringer Ingelheim
Medtronic
Express Scripts

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR VERICIGUAT


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Vericiguat

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02617550 ↗ Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients Completed Merck Sharp & Dohme Corp. Phase 1 2015-11-01 This study is intended to investigate the effect of nitroglycerin on vericiguat in patients with stable coronary artery disease (CAD). Nitroglycerin is the standard therapy to treat acute crisis of angina. Thus there is a high likelihood of co-administration of both drugs in the target indication of vericiguat, worsening heart failure (HF). Therefore, it is important to investigate the safety and tolerability of vericiguat and nitroglycerin, which may be used as unprescribed on-demand treatment by patients with acute episodes of angina pectoris.
NCT02617550 ↗ Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients Completed Bayer Phase 1 2015-11-01 This study is intended to investigate the effect of nitroglycerin on vericiguat in patients with stable coronary artery disease (CAD). Nitroglycerin is the standard therapy to treat acute crisis of angina. Thus there is a high likelihood of co-administration of both drugs in the target indication of vericiguat, worsening heart failure (HF). Therefore, it is important to investigate the safety and tolerability of vericiguat and nitroglycerin, which may be used as unprescribed on-demand treatment by patients with acute episodes of angina pectoris.
NCT02861534 ↗ A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) Completed Bayer Phase 3 2016-09-20 This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection fraction (HFrEF). The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.
NCT02861534 ↗ A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) Completed Canadian VIGOUR Centre Phase 3 2016-09-20 This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection fraction (HFrEF). The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vericiguat

Condition Name

Condition Name for Vericiguat
Intervention Trials
Heart Failure 4
Coronary Artery Disease 3
Chronic Heart Failure With Reduced Ejection Fraction 2
Chronic Heart Failure With Preserved Ejection Fraction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vericiguat
Intervention Trials
Heart Failure 6
Coronary Disease 3
Coronary Artery Disease 3
Myocardial Ischemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vericiguat

Trials by Country

Trials by Country for Vericiguat
Location Trials
United States 44
Germany 24
Japan 16
Spain 9
Italy 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vericiguat
Location Trials
Indiana 3
California 3
Virginia 3
Texas 3
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vericiguat

Clinical Trial Phase

Clinical Trial Phase for Vericiguat
Clinical Trial Phase Trials
Phase 3 2
Phase 2 1
Phase 1 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vericiguat
Clinical Trial Phase Trials
Completed 8
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vericiguat

Sponsor Name

Sponsor Name for Vericiguat
Sponsor Trials
Merck Sharp & Dohme Corp. 9
Bayer 9
Canadian VIGOUR Centre 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vericiguat
Sponsor Trials
Industry 18
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Medtronic
Boehringer Ingelheim
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.